We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...
We recently compiled a list of the 10 Firms Lead Thursday’s Rally on Better Earnings, Bargain-Hunting. In this article, we ...
CULVER CITY, Calif., January 29, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne ...
1 Day IBRX 1.60% DJIA -0.32% S&P Mid Cap 400 -0.08% Health Care/Life Sciences -0.52% ...
Upgrading IBRX stock to “Buy” due to likely 2025 catalysts: accelerating Anktiva sales, potential lung cancer approval, and expanding bladder cancer market. The stock, however, has fallen to a ...
Insider Monkey on MSN18d
Why ImmunityBio, Inc. (IBRX) Dominated Last Week’s RallyWe recently compiled a list of the These 10 Firms Dominated Last Week's Rally. In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against the other stocks ...
CULVER CITY, Calif., January 27, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun ...
CULVER CITY, Calif., January 29, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback